Moran Wealth Management LLC Purchases 2,031 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

Moran Wealth Management LLC boosted its position in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 1.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 149,551 shares of the company’s stock after acquiring an additional 2,031 shares during the quarter. Moran Wealth Management LLC’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $4,273,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Pzena Investment Management LLC raised its position in Fresenius Medical Care AG & Co. KGaA by 0.6% during the first quarter. Pzena Investment Management LLC now owns 15,377,090 shares of the company’s stock worth $382,890,000 after acquiring an additional 94,065 shares in the last quarter. Millennium Management LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 50.0% in the first quarter. Millennium Management LLC now owns 1,083,602 shares of the company’s stock valued at $26,982,000 after purchasing an additional 361,364 shares during the period. Todd Asset Management LLC bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the first quarter valued at about $12,009,000. Hennessy Advisors Inc. bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the second quarter valued at about $11,479,000. Finally, Northern Trust Corp raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 5.0% in the first quarter. Northern Trust Corp now owns 380,251 shares of the company’s stock valued at $9,468,000 after purchasing an additional 18,061 shares during the period. 8.37% of the stock is owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Stock Up 0.0%

FMS stock opened at $27.42 on Wednesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.44 and a quick ratio of 1.08. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $18.94 and a 12 month high of $30.46. The company’s 50-day moving average price is $25.44 and its two-hundred day moving average price is $26.27.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its earnings results on Tuesday, August 5th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.50 by $0.02. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. The firm had revenue of $5.54 billion for the quarter, compared to analyst estimates of $5 billion. On average, analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on FMS. Wall Street Zen lowered shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 5th. UBS Group reissued a “sell” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, September 2nd. Weiss Ratings raised shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Zacks Research raised shares of Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Finally, Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $27.80.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.